Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Where I live, legalizing MJ came about through a referendum that got placed on the ballot as a question. Voters approved it. Getting peptides to that same critical mass would be an extremely difficult undertaking. On top of that, Big Pharma is eyeing these compounds for monetization in the style of SS-31, TA-1 and Tesamorelin, and in Congress money is the one thing that works 100% of the time.indolent said:
"State laws cannot permit what federal law prohibits." If U.S. states are able to grant licenses to brick-and-mortar shops to sell cannabis—banned at the federal level—for recreational purposes with no prescription needed, then why couldn't they take the same approach with peptides (presuming in-state API manufacturing)?
On a related side note, a friend's top hypothesis regarding what "feinereich" is doing is that they are carrying out venture-capital due diligence, aiming to buy out or replicate successful grey-market suppliers ahead of potential shifts (503C and further, as the article suggests) that may not only be on the horizon but that they would actively push for. That would account for their focus on domestic, single-vial suppliers and domestic labs, plus the dollar figures that strike us non-VC ordinary folks as absurd.
That right there...! The whole profit angle.Chili777 said:
Where I live, legalizing MJ came about through a referendum that got placed on the ballot as a question. Voters approved it. Getting peptides to that same critical mass would be an extremely difficult undertaking. On top of that, Big Pharma is eyeing these compounds for monetization in the style of SS-31, TA-1 and Tesamorelin, and in Congress money is the one thing that works 100% of the time.indolent said:
"State laws cannot permit what federal law prohibits." If U.S. states are able to grant licenses to brick-and-mortar shops to sell cannabis—banned at the federal level—for recreational purposes with no prescription needed, then why couldn't they take the same approach with peptides (presuming in-state API manufacturing)?
On a related side note, a friend's top hypothesis regarding what "feinereich" is doing is that they are carrying out venture-capital due diligence, aiming to buy out or replicate successful grey-market suppliers ahead of potential shifts (503C and further, as the article suggests) that may not only be on the horizon but that they would actively push for. That would account for their focus on domestic, single-vial suppliers and domestic labs, plus the dollar figures that strike us non-VC ordinary folks as absurd.